CeriBell (NASDAQ:CBLL) CFO Sells 652 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $16,300.00. Following the completion of the sale, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at approximately $3,665,000. This represents a 0.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total transaction of $24,750.00.

CeriBell Trading Up 0.6%

Shares of CBLL stock traded up $0.15 on Friday, hitting $24.72. 220,005 shares of the company’s stock traded hands, compared to its average volume of 343,502. The stock has a market capitalization of $948.70 million, a price-to-earnings ratio of -14.05 and a beta of 0.95. The company’s fifty day simple moving average is $20.57 and its 200 day simple moving average is $19.46. CeriBell, Inc. has a one year low of $10.85 and a one year high of $25.33. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. Equities analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CBLL. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. BTIG Research lifted their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research report on Thursday. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, Canaccord Genuity Group lifted their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $24.40.

Institutional Trading of CeriBell

A number of institutional investors have recently modified their holdings of CBLL. JPMorgan Chase & Co. grew its stake in shares of CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after purchasing an additional 374,179 shares during the last quarter. Rhumbline Advisers increased its holdings in CeriBell by 109.9% during the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares during the period. New York State Common Retirement Fund raised its position in CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares during the last quarter. Quantbot Technologies LP lifted its holdings in CeriBell by 70.3% in the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after buying an additional 6,401 shares during the period. Finally, Invesco Ltd. purchased a new stake in CeriBell in the 2nd quarter worth approximately $197,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.